Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.47 |
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 5/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069486 | 0.90 | CNR2 (0.54) | BCHECNR2CNR1SIGMAR1ACHE | |
| SCHEMBL6069194 | 0.84 | BCHE (0.46) | BCHECNR2CNR1SIGMAR1ACHE | |
| SCHEMBL10831687 | 0.79 | BCHE (0.54) | BCHECNR2CNR1SIGMAR1ALDH1A1 | |
| SCHEMBL6069613 | 0.78 | CNR1 (0.51) | BCHECNR2CNR1SIGMAR1LTA4H | |
| SCHEMBL6069757 | 0.76 | CNR2 (0.54) | BCHECNR2CNR1SIGMAR1ACHE | |
| SCHEMBL30860180 | 0.75 | QPCT (0.47) | BCHECNR2CNR1DDB1CRBN | |
| SCHEMBL30860313 | 0.74 | KDM4E (0.41) | BCHECNR2CNR1ALDH1A1 | |
| SCHEMBL17678293 | 0.73 | BCHE (0.45) | BCHECNR2CNR1SIGMAR1ALDH1A1 | |
| SCHEMBL6069477 | 0.73 | CNR2 (0.41) | BCHECNR2CNR1SIGMAR1LTA4H | |
| SCHEMBL6069755 | 0.72 | MCHR1 (0.47) | BCHECNR2CNR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071182-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | BCHE 1148/4885CNR2 1318/4885CNR1 763/4885 |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | BCHE 1148/4885CNR2 1318/4885CNR1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.